Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy

Wu, Szu‐Yuan; Fang, Su-Chen; Shih, Hung-Jen; Wen, Yu Chin; Shao, Yu

doi:10.1016/j.ejca.2018.11.032

Cited by 51 publications

(81 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 89%

“…For example, a large retrospective cohort study with 249.986 Saskatchewan Men aged ≥40 years reported a substantial protective association between statin use and PCa mortality (HR, 0.73; 95% CI, 0.66‐0.81) . Wu et al reported that compare to non‐users, statin use was associated with significant reductions in all‐cause mortality (HR, 0.75; 95% CI, 0.68‐0.82) and PCa mortality (HR, 0.77; 95% CI, 0.69‐0.86) in locally advanced and metastatic PCa patients . In addition, using national Veterans Health Administration database, Anderson‐Carter et al identified 87 346 PCa patients on ADT and found that statin use was an independent predictor of improved overall survival (HR, 0.66; 95% CI, 0.63‐0.68) and PCa specific survival (HR, 0.56; 95% CI, 0.53‐0.60) .…”

Section: Discussionmentioning

confidence: 99%

“…26 Wu et al reported that compare to non-users, statin use was associated with significant reductions in all-cause mortality (HR, 0.75; 95% CI, 0.68-0.82) and PCa mortality (HR, 0.77; 95% CI, 0.69-0.86) in locally advanced and metastatic PCa patients. 27 In addition, using national Veterans Health Administration database, Anderson-Carter et al identified 87 346 PCa patients on ADT and found that statin use was an independent predictor of improved overall survival (HR, 0.66; 95% CI, 0.63-0.68) and PCa specific survival (HR, 0.56; 95% CI, 0.53-0.60). 28 However, several prior studies did not show an association between this medication and prostate cancer mortality.…”

Section: Discussionmentioning

confidence: 99%

“…Our study also revealed that men took atorvastatin, pravastatin, or rosuvastatin, but not lovastatin demonstrated a significant reduction in PCa mortality compared with non-users, which is consistent with the findings from a recent population-based cohort study using Taiwan National Health Insurance Research Data. 27 We have only one patient with fluvastatin and no patient with pitavastatin in our study, therefore no statistic survival analysis is available for the fluvastatin and with pitavastatin. It has been shown that that atorvastatin, pravastatin, and rosuvastatin are more effective at lowering triglycerides and low-density lipoprotein cholesterol and raising high-density lipoprotein cholesterol than other statins in patient with hypercholesterolemia.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer

et al. 2020

View full text Add to dashboard Cite

Background Pre‐clinical studies suggest that metformin and statins may delay prostate cancer (PCa) metastases; however, data in humans are limited. To the best of our knowledge, this is the first human study aimed to quantify the individual and joint effects of statin and metformin use among patients with high‐risk PCa. Methods This population‐based retrospective cohort study identified patients from the Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database. Exposure to metformin and statins was ascertained from Medicare Prescription Drug Event files. The association with all‐cause and PCa mortality were evaluated using Cox proportional hazard model with competing causes of death, where propensity scores were used to adjusted imbalances in covariates across groups. Results Based on 12 700 patients with high‐risk PCa, statin alone or in combination with metformin was significantly associated with reduced all‐cause mortality (Hazard Ratio [HR]: 0.89; 95% Confidence Interval [CI]: 0.83, 0.96; and HR: 0.75; 95% CI, 0.67‐0.83, respectively) and PCa mortality (HR, 0.80; 95% CI: 0.69, 0.92) and 0.64; 95% CI, d 0.51‐0.81, respectively. The effects were more pronounced in post‐diagnostic users: combination use of metformin/statins was associated with a 32% reduction in all‐cause mortality (95% CI, 0.57‐0.80), and 54% reduction in PCa mortality (95% CI, 0.30‐0.69). No significant association of metformin alone was observed with either all‐cause mortality or PCa mortality. Conclusions Statin use alone or in combination with metformin was associated with lower all‐cause and PCa mortality among high‐risk patients, particularly in post‐diagnostic settings; further studies are warranted.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, another meta‐analysis demonstrated that such a potentially beneficial effect of statins on PCa was only found in the patients receiving radiotherapy, but not in those who accepted radical prostatectomy . Intuitively, whether the effect of statins on PCa could vary along with treatment modality arouses increasing attention in clinical practice …”

Section: Introductionmentioning

confidence: 99%

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

Yang

Pang

et al. 2020

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective: To evaluate the effects of statin use on the treatment outcomes (i.e. overall survival and cancer-specific survival) among advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) or abiraterone/enzalutamide. Methods: The original studies, examining the effects of statins on the outcomes (i.e. overall survival and cancer-specific survival) among PCa patients treated with ADT or abiraterone/enzalutamide, were identified through a systematic search by two independent reviewers in the PubMed, Cochrane, Embase, American Society of Clinical Oncology and European Society of Medical Oncology databases. Databases were searched using keywords (abiraterone OR enzalutamide OR androgen deprivation therapy) AND statin. In total, nine eligible studies from 111 references were included for final analysis.Results and discussion: Statin use significantly lowered the risk of all-cause mortality (100 709 patients, HR = 0.73, 95%CI = 0.64-0.83, P < .00001) and the risk of cancerspecific mortality (100 343 patients, HR = 0.64, 95% CI = 0.53-0.77, P < .00001) in advanced PCa patients treated with ADT. The sensitivity analysis showed that the results were reliable. However, it could not generate reliable evidence in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone/ enzalutamide, as relevant studies were limited and had inconsistent results.

show abstract

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity

Zhang

Chen

et al. 2021

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Although neoadjuvant endocrine therapy (NET) is an alternative to chemotherapy for strongly hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (ERBB2)negative breast cancer, evidence is currently lacking regarding the probable survival outcomes of NET in comparison with those of neoadjuvant chemotherapy (NACT) for this cancer. OBJECTIVE To evaluate all-cause mortality among patients with strongly HR-positive and ERBB2negative breast cancer treated with NET vs NACT. DESIGN, SETTING, AND PARTICIPANTS This cohort study included patients with a diagnosis of invasive ductal carcinoma (IDC) with strong HR positivity and ERBB2 negativity, treated between

show abstract

Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy

Cited by 51 publications

References 36 publications

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity

Contact Info

Product

Resources

About